Policies or Program

• Canadian Agency for Drugs and Technologies in Health (CADTH), including Therapeutic Reviews and the Common Drug Review as it relates to reimbursement recommendations for decision-making process and framework.
• Federal Innovation agenda. Working with our Industry Associations (Innovative Medicines Canada and BIOTECanada) to ensure that innovative medicines, and our contribution to Research and Development in Canada are part of the consultation process in the development of this new innovation agenda.
• Federal Public Drug Plans, with respect to the reimbursement of drug products for the Federal plan beneficiaries
• Science and Technology Strategy, advocating for the development of a Biopharma sector in support of more research & development in Canada.
• Working with our Industry Associations (Innovative Medicines Canada and BIOTECanada) to provide industry recommendations on Canada's Biomanufacturing and Life Sciences Strategy, National Pharmacare, Intellectual property as well as pricing reforms (PMPRB)

Policies or Program, Regulation

• R&D requirements set forth through the Patent Medicines Pricing Review Board (PMPRB)

Regulation

• Patent Medicines Pricing Review Board reforms, regarding both the revised regulations and draft guidelines
• Patented Medicine Prices Review Board (PMPRB) Regulations as related to reporting requirements and pricing guidelines.
• Patented Medicines (Notice of Compliance) Regulations as it relates to regulation of intellectual property for therapeutic products. Novartis is working with our industry associations (Innovative Medicines Canada and BIOTECanada) to provide a written response to Guideline consultation process and will provide our own corporate submission.